Dad’s aggressive brain cancer vanishes after taking new drug
Groundbreaking cancer trial to recruit patients within the NHS
- A new immunotherapy drug trial for glioblastoma, the deadliest form of brain cancer, is now recruiting patients in the NHS.
- The trial follows a previous study where patient Ben Trotman's tumour vanished, and he has shown no signs of the disease for over two years, a rare outcome for glioblastoma.
- The NHS study will enrol 16 patients over 18 months, who will receive the immunotherapy drug ipilimumab before standard treatment.
- The trial was established in memory of Baroness Margaret McDonagh, who died from the disease, and was funded by over £1 million raised by her sister, Dame Siobhain McDonagh MP.
- Led by Consultant Medical Oncologist Dr Paul Mulholland, the trial aims to build on previous findings and offers significant hope for patients with this aggressive cancer.